Allermi offers a personalized telehealth allergy solution that combines and adjusts doses of up to four clinically proven active medications into a single customized nasal spray prescribed after an online questionnaire reviewed by an Allermi physician. Patients receive monthly or on-demand deliveries, a personalized treatment plan, and access to a dedicated care team for ongoing support. The company launched in California last July and is available in 28 states nationwide. Allermi reports growth of over 30% month-over-month and says over 90% of patients report superior relief compared with over-the-counter options. The product addresses a large market—roughly 110 million Americans suffer from nasal congestion and rhinitis—where only about 30% of sufferers are satisfied with existing medications. Future plans for the seed funding include continued national expansion and scaling of business, marketing, and product operations to meet growing demand.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Mar 2023